Drug intelligence / Profile preview

CVCO-701

Development stage: Unknown
Lead developer: Epizon Pharma
Administration: Oral

Overview

CVCO-701 is a drug developed by Epizon Pharma (a subsidiary of CVCO Therapeutics) to address accelerated cardiovascular calcification, a major unmet need affecting nearly all kidney disease, diabetic, and pre-diabetic patients. The drug enhances nitric oxide mobilization and has demonstrated strong activation of cancer cell death in multiple cell lines. In a Phase 2 trial in dialysis patients, CVCO-701 restored calcification inhibitor protein levels to those seen in healthy individuals, with no reported side effects. The drug also shows potential benefits in COPD by inhibiting lung elastin degradation.

Targets

sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on CVCO-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVCO-701.

Explore the full profile